Theralase Technologies Inc. reports company developments as a clinical-stage pharmaceutical developer of energy-activated small molecules for the destruction of cancer, bacteria and viruses. Its updates center on Ruvidar® (TLD-1433), including clinical and regulatory disclosures tied to non-muscle invasive bladder cancer and research into antiviral mechanisms such as HSV-1 inactivation.
Recurring announcements also cover operating and financial results, non-brokered private placements, line-of-credit financing, capital-structure disclosure, governance matters and development collaborations. The company’s news commonly links research progress with funding needs, regulatory pathways, intellectual-property considerations and commercialization risks for its small-molecule drug formulations.
Theralase Technologies (TSXV: TLT) (OTCQB: TLTFF) has successfully closed a non-brokered private placement, raising CAN $419,124 through the issuance of 1,995,829 units at CAN $0.21 per unit. Each unit includes one common share and one warrant, with warrants exercisable at CAN $0.32 per share for 5 years.
The proceeds will fund multiple initiatives including:
- Phase II Non-Muscle Invasive Bladder Cancer clinical study
- Herpes Simplex Virus treatment research
- Rutherrin® development for various solid-core tumours (brain, lung, pancreatic, muscle invasive bladder, and colorectal cancer)
- Working capital and corporate purposes
The company paid CAN $630 in broker's fees and issued 1,500 broker warrants. All securities are subject to a four-month hold period expiring August 15th, 2025.
Theralase Technologies (OTCQB: TLTFF) has announced breakthrough results for their drug Ruvidar in treating Herpes Simplex Virus Type 1 (HSV-1). In preclinical animal studies, Ruvidar (1%) demonstrated superior efficacy compared to FDA-approved treatments Acyclovir (5%) and Abreva (10% Docosanol).
Key findings show that Ruvidar completely healed HSV-1 lesions with just one daily application over 5 days, while competing treatments required 5 applications daily for 5-6 days and still failed to achieve complete healing. The drug's effectiveness is attributed to its positive charge, which enables it to block viral glycoproteins and prevent virus replication.
Following these successful results, Theralase will proceed with formulating Ruvidar into topical form, complete GLP toxicology studies, and initiate a Phase I/II adaptive clinical study to evaluate its safety and efficacy in human patients.
Theralase Technologies (TLTFF) has announced a significant breakthrough in treating BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). A patient diagnosed with Carcinoma In-Situ (CIS) has maintained a Complete Response for over 7 years following a single treatment with their light-activated RuvidarTM therapy.
The treatment involved administering Theralase's lead molecule RuvidarTM, activated by the TLC-3200 medical laser system. CIS, found in about 10% of bladder cancer cases, is an aggressive form of NMIBC with high recurrence rates. The company plans to complete its Phase II NMIBC clinical study in 2025, followed by regulatory submissions to Health Canada and FDA in 2026.
The company is also exploring RuvidarTM's potential applications in treating various conditions, from herpes simplex virus lesions to aggressive cancers like glioblastoma multiforme, non-small cell lung cancer, pancreatic cancer, and Muscle Invasive Bladder Cancer.
Theralase Technologies (TSXV: TLT) (OTCQB: TLTFF) has announced promising results for their drug Ruvidar™ in treating Herpes Simplex Virus Type 1 (HSV-1). In preclinical animal trials, Ruvidar demonstrated superior efficacy compared to standard treatments Acyclovir and Abreva.
The global HSV treatment market, valued at $2.8 billion in 2024, is projected to reach $4.7 billion by 2033, with North America holding a 37.1% market share. An estimated 3.8 billion people globally have HSV-1, highlighting significant market potential.
The research showed Ruvidar's unique mechanism of action, utilizing positive charge to block viral glycoproteins and prevent virus replication. Following these successful preclinical results, Theralase plans to begin formulating Ruvidar into topical form and commence Phase I/II adaptive clinical studies in 2025, pending funding, to evaluate its safety and efficacy in treating cold sore lesions in humans.
Theralase Technologies (TSXV: TLT) (OTCQB: TLTFF) has released its 2024 financial statements, reporting a 3% decrease in total revenue to $1,033,431 compared to 2023. The company achieved a gross margin of 54%, with cost of sales at $479,406.
Key financial metrics show decreased expenses across multiple categories: administrative expenses fell 9% to $1,734,066, and research and development expenses decreased 8% to $2,735,674. The company reported a net loss of $4,256,114 for 2024, with the Drug Division accounting for 84% of the loss.
In clinical developments, the company has treated 79 patients in Study II, with promising results: 62.5% of evaluated patients demonstrated Complete Response (CR), and 45% of those maintained CR for at least 12 months. The company plans to complete Study II enrollment by mid-2025. Additionally, Theralase is collaborating on Parkinson's Disease treatment research and advancing studies in GlioBlastoma Multiforme and Herpes Simplex Virus treatment applications.
Theralase Technologies (TSXV: TLT) (OTCQB: TLTFF) has successfully closed a non-brokered private placement offering, raising CAD $310,200 through the issuance of 1,034,002 units at CAD $0.30 per unit. Each unit includes one common share and one warrant, with warrants exercisable at CAD $0.45 per share for 5 years.
The proceeds will support the company's ongoing Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study, preclinical research and development of Rutherrin®, working capital, and general corporate purposes. The offering included participation from company insiders, who subscribed for 251,668 units totaling CAD $75,500.
A broker's fee of CAD $1,728 and 2,880 non-transferrable broker warrants were paid in connection with the offering. All securities issued are subject to a four-month hold period expiring July 12th, 2025.
Theralase Technologies (TLTFF) has announced promising interim clinical data showing improvements in both motor and non-motor function for Parkinson's Disease (PD) patients treated with their TLC-2400 Cool Laser Therapy (CLT) system.
In a triple-blind, randomized controlled study at the University of Windsor, patients received 7 treatments over 3 weeks using either active or placebo CLT systems. Key findings include:
- 11% increase in cognitive assessment scores with active treatment vs 4% with placebo
- 14% improvement in brain blood flow with active treatment vs 1% with placebo
- 19% improvement in fine motor control with active treatment vs 6% with placebo
- 9% improvement in orthostatic tolerance with active treatment vs no change with placebo
The study demonstrates that Theralase's CLT technology can non-invasively penetrate the human skull, promoting anti-inflammatory responses and stimulating dopamine production. This research is particularly significant as PD affects 1 million Americans, with treatment costs reaching $52 billion annually.
Theralase Technologies (TLTFF) has announced significant breakthroughs in treating Non-Hodgkin's Lymphoma (NHL) using their lead compound Rutherrin®. In a preclinical study, Rutherrin® demonstrated effective destruction of NHL when combined with Metformin and radiation in an animal model.
The research utilized A20 mouse lymphoma cells in a highly aggressive tumor model. The treatment protocol involved:
- Rutherrin® administered intravenously 3 times per week
- Daily Metformin injections
- Radiation 5 times per week
The most notable results came from the trimodal therapy combining all three treatments, which led to the best overall response, including one case of complete tumor regression with the mouse remaining tumor-free. NHL represents a significant market opportunity, with global market estimates reaching $16.5 billion by 2031. The disease affected approximately 544,000 new cases globally in 2020, resulting in 260,000 deaths.
Theralase Technologies (TSXV:TLT)(OTCQB:TLTFF) has successfully validated previous University of Manitoba research, demonstrating that Ruvidar™ is safe and effective in treating Herpes Simplex Virus Type 1 (HSV-1) in an animal model.
The research involved Balb/C mice infected with human HSV-1 virus. A 1% Ruvidar solution was applied topically to developed lesions once daily for 4 days, resulting in complete healing of the HSV-1 cutaneous lesions.
This breakthrough comes amid significant market opportunity, with the global HSV treatment market valued at $2.5 billion in 2023 and expected to grow at 8.1% CAGR from 2024 to 2030. Currently, an estimated 3.8 billion people under age 50 globally have HSV-1, while 520 million aged 15-49 have HSV-2. North America holds the largest market share at 32.4%.
Based on these successful results, Theralase plans to develop both a vaccine and therapeutic for HSV prevention and treatment, with clinical development to follow.
Theralase Technologies has validated previous University of Manitoba research, demonstrating that Ruvidar™ is safe and effective in treating Herpes Simplex Virus Type 1 (HSV-1) in an animal model. The research showed complete healing of HSV-1 cutaneous lesions in Balb/C mice after four days of treatment with a 1% Ruvidar solution.
The global HSV treatment market was valued at $2.5 billion in 2023, with an expected CAGR of 8.1% from 2024 to 2030. North America holds the largest market share at 32.4%. An estimated 3.8 billion people under age 50 globally have HSV-1, while 520 million people aged 15-49 have HSV-2.
Based on these successful results, Theralase plans to develop both a vaccine and therapeutic for HSV prevention and treatment, with clinical development to follow.